PolyPid Ltd
PYPD
View Detailed Chart
3.970USD
+0.050+1.28%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
66.04MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.28%
5 Days
+1.28%
1 Month
+10.28%
6 Months
+21.04%
Year to Date
+30.59%
1 Year
+23.29%
View Detailed Chart
TradingKey Stock Score of PolyPid Ltd
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PolyPid Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
12.250
Target Price
+207.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
PolyPid Ltd Highlights
StrengthsRisks
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Undervalued
The company’s latest PE is -0.96, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.45M shares, increasing 22.47% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
PolyPid Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
PolyPid Ltd Info
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Ticker SymbolPYPD
CompanyPolyPid Ltd
CEOAkselbrad (Dikla Czaczkes)
Websitehttps://www.polypid.com
FAQs
What is the current price of PolyPid Ltd (PYPD)?
The current price of PolyPid Ltd (PYPD) is 3.970.
What is the symbol of PolyPid Ltd?
The ticker symbol of PolyPid Ltd is PYPD.
What is the 52-week high of PolyPid Ltd?
The 52-week high of PolyPid Ltd is 4.070.
What is the 52-week low of PolyPid Ltd?
The 52-week low of PolyPid Ltd is 2.300.
What is the market capitalization of PolyPid Ltd?
The market capitalization of PolyPid Ltd is 66.04M.
What is the net income of PolyPid Ltd?
The net income of PolyPid Ltd is -29.02M.
Is PolyPid Ltd (PYPD) currently rated as Buy, Hold, or Sell?
According to analysts, PolyPid Ltd (PYPD) has an overall rating of Buy, with a price target of 12.250.
What is the Earnings Per Share (EPS TTM) of PolyPid Ltd (PYPD)?
The Earnings Per Share (EPS TTM) of PolyPid Ltd (PYPD) is -2.807.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
